Free tool
FAERS Monitor: Alrex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020803 or its brand name (Alrex, Loteprednol Etabonate). Reports on generic versions are filed under their own applications.
Reports
1,209
Serious
434
36% of reports
Hospitalization
152
Death reported
25
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain178
- eye irritation143
- drug ineffective108
- off label use85
- headache79
- ocular hyperaemia73
- fatigue62
- photophobia57
- eye swelling48
- vision blurred48
- lacrimation increased44
- dry eye43
- pain43
- product dose omission issue42
- condition aggravated41
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 8 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 15 |
| 2009 | 12 |
| 2010 | 29 |
| 2011 | 15 |
| 2012 | 23 |
| 2013 | 15 |
| 2014 | 16 |
| 2015 | 42 |
| 2016 | 54 |
| 2017 | 46 |
| 2018 | 62 |
| 2019 | 63 |
| 2020 | 65 |
| 2021 | 88 |
| 2022 | 95 |
| 2023 | 121 |
| 2024 | 159 |
| 2025 | 146 |
| 2026 | 125 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,950 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 178 | 55.1 | 48.1 | 9,389 |
| photophobiaSignal | 57 | 52.9 | 41.0 | 2,843 |
| eye irritationSignal | 143 | 43.3 | 37.1 | 5,872 |
| ocular hyperaemiaSignal | 73 | 26.8 | 21.5 | 1,789 |
| lacrimation increasedSignal | 44 | 25.4 | 19.0 | 1,006 |
| eye swellingSignal | 48 | 22.5 | 17.0 | 964 |
| dry eyeSignal | 43 | 15.0 | 11.2 | 549 |
| vision blurredSignal | 48 | 6.1 | 4.6 | 200 |
| product dose omission issueSignal | 42 | 2.5 | 1.8 | 36 |
| condition aggravatedSignal | 41 | 2.3 | 1.7 | 31 |
| headacheSignal | 79 | 2.2 | 1.8 | 52 |
| off label use | 85 | 1.7 | 1.4 | 24 |
| drug ineffective | 108 | 1.4 | 1.2 | 14 |
| fatigue | 62 | 1.4 | 1.1 | 7 |
| pain | 43 | 1.2 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.